Literature DB >> 34160743

Management of tandem occlusions in patients who receive rtPA.

Keaton S Smetana1, Amanda Zakeri2, Jaydevsinh Dolia3, Allyson Huttinger4, Casey C May1, Patrick Youssef2, Bradley A Gross3, Shahid M Nimjee5.   

Abstract

BACKGROUND: Tandem occlusions exist in 17-32% of large vessel occlusion (LVO) strokes. A significant concern is bleeding when carotid stenting is performed in tandem with thrombectomy due the administration of antiplatelet agents such as glycoprotein IIb/IIIa inhibitors (GP2b3aI) after receiving rtPA, but data are limited in this setting.
METHODS: A mutlicenter, retrospective chart review was conducted at two comprehensive stroke centers to assess the safety and efficacy of using GP2b3aI to facilitate carotid stent placement simultaneously with endovascular thrombectomy in patients who have received rtPA.
RESULTS: Overall, 32 patients were included in this study, with average age of 66.3 ± 10.4 years and predominantly male (87.5%). The cause of stroke was mostly large artery atherosclerosis (59.4%) and the thrombectomy target vessels were typically first- or second segment middle cerebral artery (37.5% and 31.3%). Time from symptom onset to rtPA bolus was 1.8 h [interquartile range (IQR) 1.5-2.7], rtPA bolus to first pass was 2 h [IQR 1.5-3.1], rtPA bolus to GP2b3aI bolus was 2 h [IQR 1.6-3.5], and rtPA bolus to aspirin and clopidogrel administration was 4.3 h [IQR 2.6-8.9] and 6.6 h [IQR 4.5-11.6] respectively. No patients had acute in-stent thrombosis or post-op bleeding from the access site. Two patients (6.3%) had significant hemorrhagic conversion.
CONCLUSION: The use of GP2b3aI in the setting of tandem occlusions that required emergent stent placement post-rtPA appears safe and effective. Given the small sample size, these findings should be interpreted cautiously, and need to be confirmed in a larger patient population.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Carotid stenosis; Glycoproteins IIb-IIIa inhibitor; Ischemic stroke; Tandem lesion; Thrombectomy; Tissue plasminogen activator

Mesh:

Substances:

Year:  2021        PMID: 34160743     DOI: 10.1007/s11239-021-02510-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

1.  Stent-Retriever Thrombectomy for Stroke.

Authors:  Jeffrey L Saver; Mayank Goyal; Hans-Christoph Diener
Journal:  N Engl J Med       Date:  2015-09-10       Impact factor: 91.245

2.  Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.

Authors:  K Stangl; M Laule; B Tenckhoff; V Stangl; V Gliech; P Dübel; A Grohmann; C Melzer; J Langel; K D Wernecke; G Baumann; S Ziemer
Journal:  Am J Cardiol       Date:  1998-04-01       Impact factor: 2.778

3.  Thrombectomy 6 to 24 Hours after Stroke.

Authors:  Tudor G Jovin; Raul G Nogueira
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

4.  Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation.

Authors:  Xiaoyan Gong; Annette Ahner; Ariel Roldan; Gergely L Lukacs; Patrick H Thibodeau; Raymond A Frizzell
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

5.  Thrombectomy within 8 hours after symptom onset in ischemic stroke.

Authors:  Tudor G Jovin; Angel Chamorro; Erik Cobo; María A de Miquel; Carlos A Molina; Alex Rovira; Luis San Román; Joaquín Serena; Sonia Abilleira; Marc Ribó; Mònica Millán; Xabier Urra; Pere Cardona; Elena López-Cancio; Alejandro Tomasello; Carlos Castaño; Jordi Blasco; Lucía Aja; Laura Dorado; Helena Quesada; Marta Rubiera; María Hernandez-Pérez; Mayank Goyal; Andrew M Demchuk; Rüdiger von Kummer; Miquel Gallofré; Antoni Dávalos
Journal:  N Engl J Med       Date:  2015-04-17       Impact factor: 91.245

6.  A randomized trial of intraarterial treatment for acute ischemic stroke.

Authors:  Olvert A Berkhemer; Puck S S Fransen; Debbie Beumer; Lucie A van den Berg; Hester F Lingsma; Albert J Yoo; Wouter J Schonewille; Jan Albert Vos; Paul J Nederkoorn; Marieke J H Wermer; Marianne A A van Walderveen; Julie Staals; Jeannette Hofmeijer; Jacques A van Oostayen; Geert J Lycklama à Nijeholt; Jelis Boiten; Patrick A Brouwer; Bart J Emmer; Sebastiaan F de Bruijn; Lukas C van Dijk; L Jaap Kappelle; Rob H Lo; Ewoud J van Dijk; Joost de Vries; Paul L M de Kort; Willem Jan J van Rooij; Jan S P van den Berg; Boudewijn A A M van Hasselt; Leo A M Aerden; René J Dallinga; Marieke C Visser; Joseph C J Bot; Patrick C Vroomen; Omid Eshghi; Tobien H C M L Schreuder; Roel J J Heijboer; Koos Keizer; Alexander V Tielbeek; Heleen M den Hertog; Dick G Gerrits; Renske M van den Berg-Vos; Giorgos B Karas; Ewout W Steyerberg; H Zwenneke Flach; Henk A Marquering; Marieke E S Sprengers; Sjoerd F M Jenniskens; Ludo F M Beenen; René van den Berg; Peter J Koudstaal; Wim H van Zwam; Yvo B W E M Roos; Aad van der Lugt; Robert J van Oostenbrugge; Charles B L M Majoie; Diederik W J Dippel
Journal:  N Engl J Med       Date:  2014-12-17       Impact factor: 91.245

7.  Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.

Authors:  Alex C Spyropoulos; Walter Ageno; Gregory W Albers; C Gregory Elliott; Jonathan L Halperin; William R Hiatt; Gregory A Maynard; P Gabriel Steg; Jeffrey I Weitz; Eunyoung Suh; Theodore E Spiro; Elliot S Barnathan; Gary E Raskob
Journal:  N Engl J Med       Date:  2018-08-26       Impact factor: 91.245

Review 8.  Clinical perspectives and therapeutics of thrombolysis.

Authors:  Ijaz A Khan; Ramesh M Gowda
Journal:  Int J Cardiol       Date:  2003-10       Impact factor: 4.164

9.  Home Use of an Artificial Beta Cell in Type 1 Diabetes.

Authors:  H Thabit; M Tauschmann; J M Allen; L Leelarathna; S Hartnell; M E Wilinska; C L Acerini; S Dellweg; C Benesch; L Heinemann; J K Mader; M Holzer; H Kojzar; J Exall; J Yong; J Pichierri; K D Barnard; C Kollman; P Cheng; P C Hindmarsh; F M Campbell; S Arnolds; T R Pieber; M L Evans; D B Dunger; R Hovorka
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.